For ischemic brain damage, is preclinical evidence of neuroprotection by presynaptic blockade of glutamate release enough?

Medical Hypotheses

Volumn 54, Issue 1, 2000, Pages 77-79

  Nava Ocampo, A A ^a,b   Reyes Perez H ^a,b   Bello Ramirez A M ^a,b   Mansilla Olivares, A ^a,b   Ponce Monter, H ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b CENTRO DE INVESTIGACIONES QUÍMICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GLUTAMIC ACID; LAMOTRIGINE; LIFARIZINE; NEUROPROTECTIVE AGENT; PROPENTOFYLLINE; RILUZOLE; RP 66055; SIPATRIGINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; META ANALYSIS; NEUROPROTECTION; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SHORT SURVEY; SYNAPTIC INHIBITION;

ANIMALIA;

EID: 0343340386     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0831     Document Type: Article

References (13)

1. Faden A. T. Pharmacological treatment of central nervous system trauma. Pharmacol Toxicol. 78:1996;12-17
2. Muri K. W., Lees K. R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513
3. Fisher M., Jones S., Sacco R. L. Prophylactic neuroprotection for cerebral ischemia. Stroke. 25:1994;1075-1080
4. Lekieffre D., Meldrum B. S. The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats. A microdialysis and histological study. Neuroscience. 56:1993;93-99
5. Sun F. Y., Faden A. I. Neuroprotective effects of 619C89, a use-dependent sodium channel blocker, in rat traumatic brain injury. Brain Res. 673:1995;133-140
6. D'Agostino R. B., Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther. 58:1995;605-616
7. Daly L. E., Bourke G. J., McGilvray J. Interpretation and uses of medical statistics. 1992;Blackwell Scientific, Oxford. p. 106-110
8. Pratt J., Rataud J., Bardot F. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci Lett. 140:1992;225-230
9. Graham S. H., Chen J., Sharp F. R., Simon R. P. Limiting ischemic injury by inhibition of excitatory amino acid release. J Cerebr Blood F Met. 13:1993;88-97
10. Leach M. J., Swan J. H., Eisenthal D., Dposon M., Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke. 24:1993;1063-1067
11. Rataud J., Debarnot F., Mary V., Pratt J., Stutzmann J. M. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett. 172:1994;19-23
12. Matsumoto K., Sakaki T., Kohmura E., Hayakawa T., Yamada K. Amelioration of ischemic brain damage by the preischemic administration of propentofylline (HWA285) in a rat focal ischemia. Brain Res. 723:1996;228-230
13. Bloom F. E. Neurotransmission and the central nervous system. Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W., Goodman-Gilman A. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996;267-293 McGraw-Hill Company, New York